Fishing for Insight
The power of metabolomics lies in casting a wide net.
Coral Barbas |
Analytical chemistry has always been the key to advances in scientific knowledge. It bridges the gap between a hypothesis and a theory by providing tools to test and validate our ideas. Nowadays, its power is greater than ever. Breathtaking advances in instrumental analysis and computational capabilities make it possible to separate and measure myriad compounds in very complex samples. In turn, these advances have opened the door to –omics technologies – including metabolomics.
Metabolomics is a powerful approach because metabolite concentrations, unlike genes or proteins, directly reflect the biochemical activity of a biological system. Metabolomics represents the phenotype, and gives real-time data on the end points that matter (for example, illness or response to a drug).
Classical research is based on generating a hypothesis and developing the necessary assays to prove or disregard the hypothesis, which is time consuming and limited. New technologies have given us the opportunity to carry out a different type of research, looking at all the changes that occur in a system.
I often compare it with fishing. Traditional research is like fishing for salmon – you select the best place, time, rod and bait for the job, and you come home either with a salmon, or with nothing. Metabolomics is like fishing from a boat with a huge fishing net. You catch everything that is there, and while some of your haul will be plastic bags and seaweed, you are likely to find a variety of interesting fish. Every so often, you might even get lucky and catch a mermaid!
Detecting changes to the concentrations of metabolites in a perturbed system by differential analysis opens up an unlimited number of applications. We can identify biomarkers with potential as diagnostic markers, gather data to stratify patients or predict the trajectory of a disease over time. We can interpret metabolic changes to understand the mechanism of a disease, identify a target, and design new therapies. In cellular assays, metabolomics can give a broad picture of all the changes produced in response to a treatment. In summary, metabolomics can provide answers in basic research, personalized medicine, drug design, biotechnology and many other fields.
Luckily for analytical chemistry researchers, there is a lot of space for improvement in metabolomics workflow. To name just a few:
- The whole process should be validated to ensure reproducibility in results.
- Validation parameters and quality control procedures need to be established, with a joint effort of societies, journals and research groups to come to consensus.
- Metabolite identification is still one of the bottlenecks, together with data interpretation; in that regard, different groups and companies are working on cured databases and intelligent software systems.
- Reproducible ionization sources in LC are still a challenge for companies devoted to technical development.
On a personal level, I have found metabolomics to be a very rewarding field of analytical chemistry. Firstly, it gives you the opportunity to work with state-of-the-art instrumental techniques and chemometric tools. Secondly, the nature of the field means that you have the opportunity to participate in multi-disciplinary groups, learn from different fields, and develop the ability to explain your knowledge to people from different backgrounds. It’s a field in which you are always learning – from every project, every topic, every disease, and every research objective – which is both challenging and amazing.
Coral Barbas’ research career started at Biochemistry Lab with Prof Emilio Herrera, developing and validating chromatographic methods for bioanalysis. In 2005-06 she obtained a Marie Curie fellowship for Experienced Researchers at Kings College London, where she was introduced to Metabolomics concepts and workflow.
Once back to San Pablo CEU University she succeeded in getting funding from public and private sources as well as from the university to establish the Centre for Metabolomics and Bioanalysis (CEMBIO), that she has headed since then. Currently CEMBIO is a leading lab in Metabolomics using mass spectrometry coupled to different separation techniques (GC-MS, LC-MS and CE-MS). It offers: searching metabolic changes without a priori hypothesis to unveil mechanism of drug action, toxicity or resistance, patient stratification based on non-target metabolomics, as well as target pathway analysis. CEMBIO has the capacity for tackling aspects such as experimental design, analytical methods, appropriate statistical methods for metabolomics data treatment and biochemical interpretation.
Techniques for target analysis are also available and method development is part of the expertise. With these purposes CEMBIO´s group includes over 20 researchers in all levels from technicians to pre-doc, postdocs and staff with expertise in analytical techniques, statistics, pharmacy and biochemistry.
Currently she is Visiting Professor at Imperial College London (UK) collaborating with Prof Jeremy Nicholson´s group and at Bialystok Medical University (Poland) collaborating with the doctorate program in “OMICS” technologies. She has published over 160 research papers all in journals with high impact factors.